the most common presenting symptoms are palpitations, breathlessness, dizziness and syncope although as many as 25-30% do not have symptoms. 10, 5 therefore, many fail to present for treatment, despite having a greatly elevated risk of stroke.
the management of aF in UK primary care presents a resource challenge that is set to rise as our population ages. the burden on resources comes mainly through referrals and hospital admissions. 11 there is an opportunity to identify potential efficiencies, if strategies to address these issues are incorporated into planning and policy development.
11, 12 the challenge to resources, through treatment of aF, is outweighed by the current challenge on resources that exists in managing preventable aF related strokes.
this document is primarily aimed to be used by primary care practitioners, managers and commissioners of services.
Atrial fibrillation (AF) is the most common sustained adult cardiac arrhythmia. there are currently over 1 million 1, 2, 3, 4 people diagnosed with AF in the UK, with many more (25-30%) who are thought to have the condition without it being diagnosed yet. 5, 6 the prevalence of aF increases with age, and to more than 15% in those aged 75 years and over. 6 aF increases risk of death, stroke, thromboembolic events, heart failure, vascular dementia, hospitalisations, reduced quality of life and diminished exercise capacity. 5 aF is costly in terms of increased mortality, morbidity and reduced quality of life. 7 within the UK, it is a condition that is not always managed well, with patients reporting inadequate explanations of their condition and treatment options. 7 audits across the UK confirm that the use of anticoagulation to reduce the risk of aF related stroke is underutilised. 7 aF related strokes are more debilitating, with those affected being less likely to get back to independent living and less likely to survive. 
11,600
aF-related strokes could be averted each year if everyone with aF received appropriate treatment including anticoagulation 14 Around 50% of people with an AF-related stroke will not survive beyond 12 months and those that do will suffer increased disability compared to those who have non-aF related strokes 8, 9 of aF-related stroke if left untreated 8 
5-fold increase x5
develop and evidence the case to promote and enable optimal management of people living with aF, from early diagnosis through to living with this long-term condition.
to improve the identification, diagnosis, risk stratification and optimal management of people with aF to reduce the risk of aFrelated stroke events and known complications such as heart failure (HF), premature mortality, reduced quality of life and vascular dementia. 
Challenge of the Increasing Prevalence of Atrial Fibrillation
• The prevalence of AF is expected to significantly increase from 1.6% 18 (true UK prevalence is estimated to actually be 2.4% 19 ) due to the growing population of elderly people and the increasing incidence and prevalence of those living longer with associated long term conditions. 20 • There are significant gaps in primary care with substantial numbers of cases being undiagnosed. of those treated for aF, large proportions are under treated and therefore remain at increased risk.
• Optimal management of those with hypertension and HF will reduce the numbers of those developing permanent aF.
5
• HF is both a consequence and a cause of AF; the prevalence of AF in those with HF in the Framingham Heart Study ranged between 5% (mild HF) and 50% (severe HF).
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AF Detection and Stroke Prevention
• Those living with AF have a fivefold increase in their stroke risk, depending upon the presence of various stroke risk factors.
15
To reduce the likelihood of AF leading to stroke (with the resultant impact and devastation being suffered by individuals/family), we need to ensure that individuals receive appropriate treatment.
• It is estimated that the incidence of stroke is two to seven times higher in those with non-valvular aF compared to those without aF.
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• The stroke risk associated with AF does not correlate to the existence or severity of symptoms.
• Having AF increases the individual's risk of stroke, developing HF, 21 reduced quality of life and increased risk of death. ü Increase the frequency of pulse checks; opportunistic case finding for AF (pulse checks) in those aged 65 years and older is cost effective in comparison to relying on patients to present with symptoms. 23 ü Target the use of aspirin; aspirin for stroke prophylaxis in aF is now not recommended as it does not provide effective stroke risk reduction but increases the risk of major bleeding (including intracranial bleeds). 6 ü adopt an evidence based approach to stroke prevention in aF. addressing fears, held by clinicians and patients alike, regarding bleeding with anticoagulation is of vital importance. Using the evidence based cha 2 dS 2 -VaSc Score (http://www.acc.org/tools-and-practicesupport/clinical-toolkits/atrial-fibrillation-afib) is recommended for stroke risk assessment for those with non valvular AF (i.e. AF not secondary to significant valve disease, such as mitral stenosis/ regurgitation and aortic stenosis).
ü ensure that anticoagulation is discussed and offered to individuals with a score of ≥2, and considered for all those with a score of 1, except if they are aged <65 years and the point is due to female gender alone. ü ensure that those on non-vitamin K antagonists, such as warfarin, have a satisfactory time in treatment range (65% minimum). There is good evidence to show that a patient self-monitoring can be more effective in preventing strokes than the healthcare professional in a clinic. Selfmonitoring of oral anticoagulation: a systematic review and meta-analysis of individual patient data (http://www.thelancet.com/journals/ lancet/article/PIIS0140-6736(11)61294-4/ abstract) ü Make sure that those with poor time in treatment range are reviewed; NICE guidance highlights that individuals who have a poor time in treatment range with vitamin K antagonists do less well, having more bleeds and strokes due to iNR levels being too high (risk of bleeding) or too low (risk of stroke). If their time in treatment range cannot be improved they should be considered for alternative stroke prevention measures. 6 ü Encourage a systematic/audit approach to identify those who remain on anti-platelet therapy, in addition to anticoagulation; in stable vascular disease it has been shown that using anti-platelet therapy in addition to anti-coagulation increases the risk of major bleeding without reducing mortality or myocardial infaction. 16, 24 Some patients may need a short period of time on dual or even triple therapy, (e.g. post coronary stent) their individual risk versus benefit needs to be carefully considered and discussed with them by a specialist. 24 ü promote the use of haS-Bled Score 7 (http://www.acc.org/tools-and-practicesupport/clinical-toolkits/atrial-fibrillationafib) to assess bleeding risk in patients starting anticoagulation in order to demonstrate how bleeding risk can be reduced by risk factor modification and monitoring. ü Improved public/patient understandingpersonalised package of care including: -stroke awareness and measures to prevent stroke -who to contact for advice as indicated -psychological support -up-to date comprehensive education and support -adults with aF on long-term vitamin K antagonist therapy are achieving satisfactory time in treatment range (>65%) and supported to self-manage with a coagulometer.
ü Prompt referral for those with symptomatic AF individuals whose symptoms of aF fail to respond to treatment need to be referred for specialist management within four weeks. 6 ü Recognising AF as a long-term condition the benefits and risks of treatment and progression of aF need regular review and discussion with individuals. these discussions will encompass issues such as anticoagulation, symptoms and onward monitoring. 
Information
Staff -Professional Development and Support
there remains a gap in UK primary care between best practice and actual practice in terms of diagnosis and prescribing decisions such as under prescribing of beta-blockers, rate limiting calcium antagonists and thromboprophylaxis. 11, 12 conversely, there remains an undesirable high prevalence of prescribing digoxin as monotherapy.
11 education for healthcare professionals will need to include case finding, anticoagulation evidence and options, time in treatment range, utilising patient decisions aids and promoting self-monitoring by individuals with aF.
Leadership -Local Champions
there needs to be local champions at all levels (primary care practitioners, managers and commissioners) who will lead effective change in the arena of aF and stroke prevention. Further improvement may come through exploring alternative models such as pharmacist support for adherence and warfarin control. iNteGRated caRe aF is a long term condition requiring integrated care across primary, secondary, tertiary and social care to ensure that patient pathways are seamless, safe and person centred. the BhF has recently funded and externally evaluated nine integrated care projects, including two projects which incorporated the management of aF. Both projects were funded for 2 years for two 0.5wte specialist nurses. NHS Tayside Project -There were three strands around arrhythmia care; one included establishing rapid access aF clinics across the health Board. this project has now successfully been implemented, operating at full capacity and now sustained by the NhS health Board. NHS Lanarkshire Project -The project involved audit and education for primary care clinicians as well as education for secondary care specialist nurses. after one year, it showed an increase in the prescribing of anticoagulants and an expected reduction of 70 AF related strokes, which is a reduction of 14% from baseline. the full external evaluation can now be read at: http://europe.icfi.com/BHF/IC_Evaluation_ Final%20Report.pdf 
Patient Education
It is essential that healthcare professionals offer individuals with aF support and education, appropriate to their needs in order to promote their ability to make informed decisions and manage their condition. The NICE (CG 180) 7 recommend that individuals with aF are supported to understand cause, effects and possible complications of AF. improved understanding of these issues is pivotal in motivating individuals to engage with evidenced based treatment, particularly for those who are asymptomatic with AF (one third or 25-30%). 
Top 5 facts
How and why we could do better
1.
case identification of aF by pulse checks in those aged 65 years and older is effective; it is a great way of identifying aF before it presents in the form of morbidity or mortality.
2.
the majority of individuals with aF benefit from anticoagulation. The benefit/risk of treatment should be calculated, using the cha 2 dS 2 -VaSc and haS-Bled tools and be discussed with those being considered for treatment.
3.
evidence is clear that aspirin is never adequate stroke prevention therapy, by itself, for those with aF and at significant risk of stroke.
4.
people with aF should have optimal heart rate control and be symptom free. those who remain symptomatic despite optimal heart rate control should be referred for specialist management.
5.
people with aF should receive information on their condition, be actively involved in all decisions around their care and be supported to self-manage their long term condition.
Case study
Cardiovascular Disease Clinical Development Coordinator role
In 2012 the BHF introduced and developed the Practice Development Coordinator (PDC) role, now called the cardiovascular disease clinical development coordinator. the role, delivered by specialist cVd nurses, provides education and professional development support to hcps working in the community to enable the best quality care and services for people at risk of or with a diagnosis of cVd. it also addresses health inequalities by targeting effort in those areas where cVd is most prevalent, and where gaps in care and management exist. education on atrial fibrillation management is a common request from practice nurses and Gps.
an external evaluation of the role undertaken in 2014 to assess the performance and impact of the pdc programme of work demonstrated a number of high value impacts. 25 
